Loading…
No business profile yet.
Size Australian Unity Ltd Pref (AYUPA.AX) is an Australia Health Care company (Medical/Nursing Services) with a market value of $353M, the 308th largest of 316 Australia companies the cockpit tracks. Shares closed at A$66.44 on 6 Nov 2026.
Performance Over six months the shares gained 6.4%, against -2.5% for the median peer and +4.1% for the Australia market (cap-weighted) — 6th highest of 19 in its peer set.
Growth Revenue was unchanged over the last twelve months (peer median +6.7%); the operating margin is -2.3% (peer median 8.4%).
Valuation It trades at 0.40× book value against a peer median of 1.80× (cheapest of 20).
Price implies The share price implies a return on equity of about 4.6%; Australian Unity Ltd Pref delivers -12.4%, so the price asks more than the business earns today.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | A$2.53B | A$2.53B | A$2.53B | A$2.04B | A$1.78B |
| Revenue growth | — | 0% | +24% | +15% | — |
| Net income | -A$160M | -A$160M | A$29.3M | -A$24.0M | A$56.8M |
| Free cash flow | A$170M | A$170M | A$46.8M | A$163M | A$2.46M |
| Capital expenditure | A$41.1M | A$41.1M | A$83.6M | A$43.5M | A$39.8M |
| Total debt | n/a | A$551M | A$674M | A$2.20B | A$1.80B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AYUPA.AX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +11.3% | -6.2% | 5th highest of 21 |
| 6-month return | +6.4% | -2.5% | 6th highest of 19 |
| Return on equity | -12.4% | 2.6% | 2nd lowest of 20 |
| Price / book | 0.40× | 1.80× | cheapest of 20 |
| ROE the price implies | 4.6% | 14.2% | least demanding of 20 |
| ROE delivered | -12.4% | 1.4% | 2nd lowest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | ROE | Price / book | Implied ROE | Delivered ROE |
|---|---|---|---|---|---|---|---|---|
| Australian Unity Ltd Pref AYUPA.AX | Australia | $353M | +6% | 0% | -12% | 0.40× | 4.6% | -12.4% |
| NIOX NIOX.L | United Kingdom | $349M | +2% | +3% | 11% | 4.07× | 18.5% | 10.7% |
| Auna AUNA | United States | $346M | -8% | +17% | 1% | 0.64× | 6.3% | 0.8% |
| Oncology Institute STLN | United States | $362M | n/a | +38% | n/a | n/a | n/a | n/a |
| M1 Kliniken M12.DE | Germany | $376M | +3% | -28% | 17% | 3.01× | 14.2% | 16.7% |
| Universal Vision Biotechnology 3218.TWO | Taiwan | $324M | -7% | 0% | 32% | 2.77× | 7.7% | 31.7% |
| Tellgen 300642.SZ | China | $387M | -3% | +5% | 1% | 1.81× | 19.6% | 1.3% |
| ADICON 9860.HK | Hong Kong | $408M | +9% | +1% | 1% | 1.56× | 8.4% | 1.4% |
| Australian Clinical Labs ACL.AX | Australia | $419M | +74% | -1% | 15% | 4.01× | 35.7% | 14.8% |
| Jeena Sikho Lifecare JSLL.NS | India | $424M | -56% | +162% | 60% | 8.58× | 87.1% | n/a |
| Integral Diagnostics IDX.AX | Australia | $450M | -21% | +26% | 3% | 0.96× | 8.5% | 3.2% |
| JS Link 127120.KS | South Korea | $481M | -57% | +51% | -7% | 5.85× | 29.4% | -7.4% |
| Strata Critical Medical SRTA | United States | $497M | 0% | +23% | -8% | 1.80× | 29.4% | -7.6% |
| Shanghai Labway Clinical Laboratory 301060.SZ | China | $593M | -4% | -19% | 3% | 2.52× | 16.9% | 2.6% |
| Nephrocare Health Services NEPHROPLUS.NS | India | $639M | +10% | +33% | 9% | 5.09× | 52.1% | n/a |
| Fulgent Genetics FLGT | United States | $653M | +49% | +7% | -8% | 0.65× | 7.5% | -8.0% |
| GMR Solutions GMRS | United States | $672M | n/a | -4% | 26% | 0.85× | 5.9% | n/a |
| HK inno.N 195940.KS | South Korea | $745M | -32% | +7% | 6% | 0.76× | 5.1% | n/a |
| WELL Health Technologies WELL.TO | Canada | $760M | -5% | +39% | 0% | 1.28× | 12.0% | 0.5% |
| Ginkgo Bioworks DNA | United States | $760M | +26% | -52% | -57% | 1.63× | 20.3% | -57.1% |
| Jinxin Fertility 1951.HK | Hong Kong | $800M | -2% | +7% | 2% | 0.60× | 8.5% | 1.9% |